MULTICENTER TRIAL OF OLMESARTAN. MAIN RESULTS

被引：0

作者：

Ageev, F. T. ^{[1
]}

Svirida, O. N. ^{[1
]}

机构：

[1] Cardiol Res Ctr, AL Myasnikov Res Inst Cardiol, Moscow 121552, Russia

来源：

TERAPEVTICHESKII ARKHIV | 2011年 / 83卷 / 09期

关键词：

olmesartan; angiotensin II receptor blocker; arterial pressure; diabetes mellitus; organ protection; C-REACTIVE PROTEIN; BLOOD-PRESSURE; CARDIOVASCULAR OUTCOMES; HYPERTENSIVE PATIENTS; RANDOMIZED-TRIAL; MEDOXOMIL; DISEASE; RISK; INFLAMMATION; MONOTHERAPY;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Development and introduction into practice of medicines reducing activity of the renin-angiotensin-aldosteron system the key element of which is angiotensin II (ATII) resulted in a significant improvement of efficacy of cardiovascular diseases treatment. Angiotensin converting enzyme (ACE) inhibitors and ATII receptor blockers (BRA II) effectively reduce arterial pressure, have a nephroprotective action in patients with diabetes mellitus, inhibit development of left ventricular hypertrophy. Unlike ACE inhibitors, BRA II do not exhibit the phenomenon of ATII concentration escape, they completely depress ATII interaction with AT1-receptors while AT2-receptors keep their ability to interact with this hormone. High probability of target arterial pressure achievement in the treatment with BRA II encourage higher compliance of the patients. The review of multicenter trials performed in 2007-2010 concerns a new BRA II representative - olmesartan medoxomil (OM). The trials run in two directions: hypotensive activity of OM and vaso- and other organ-protective OM properties.

引用

页码：54 / 60

页数：7

共 48 条

[1] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].

Albert, MA ;

Danielson, E ;

Rifai, N ;

Ridker, PM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70

[2]

[Anonymous], NCT00923091 CLINICAL

[3] Blood pressure, C-reactive protein, and risk of future cardiovascular events [J].

Blake, GJ ;

Rifai, N ;

Buring, JE ;

Ridker, PM .

CIRCULATION, 2003, 108 (24) :2993-2999

[4] Vascular inflammation and the renin-angiotensin system [J].

Brasier, AR ;

Recinos, A ;

Eledrisi, MS .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (08) :1257-1266

[5] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[6]

Chalmers J, 1999, J HYPERTENS, V17, P151

[7] Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [J].

Curb, JD ;

Pressel, SL ;

Cutler, JA ;

Savage, PJ ;

Applegate, WB ;

Black, H ;

Camel, G ;

Davis, BR ;

Frost, PH ;

Gonzalez, N ;

Guthrie, G ;

Oberman, A ;

Rutan, GH ;

Stamler, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (23) :1886-1892

[8]

Cushman William C, 2002, J Clin Hypertens (Greenwich), V4, P393

[9]

DEDOV II, 2000, DIABET NEFROPATIYA

[10] Impact of infectious burden on extent and long-term prognosis of atherosclerosis [J].

Espinola-Klein, C ;

Rupprecht, HJ ;

Blankenberg, S ;

Bickel, C ;

Kopp, H ;

Rippin, G ;

Victor, A ;

Hafner, G ;

Schlumberger, W ;

Meyer, J .

CIRCULATION, 2002, 105 (01) :15-21

← 1 2 3 4 5 →